EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report

Ayushi Gianchandani, Darshana Desai, Janani Sambath, Darshana Patil, Prashant Kumar, Shambhavi Singh, Chetan Madre, Ruturaj Deshpande, Anjali Parab, Niyati Shah, Darshit Shah, Pritam Kataria und 6 weitere

Journal of Immunotherapy and Precision Oncology · 2025-08 · 8 (3) · 206-211

DOI: 10.36401/jipo-25-7 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Immunotherapy and Precision Oncology, 2025-08. Verfasst von Ayushi Gianchandani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College London, London, United Kingdom. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non–small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to immunotherapy. We report a case of oligometastatic PSC harboring compound EGFR mutations (p.G719C and S768I). The patient exhibited disease progression despite sequential treatment with EGFR TKIs, including osimertinib, afatinib, and mobocertinib, in combination with chemotherapy. The treatment strategy was then shifted to immunotherapy with pembrolizumab alongside carboplatin and paclitaxel, leading to a remarkable response. Given the oligometastatic nature of the disease and the sustained response, bilateral adrenalectomy was performed, revealing a complete pathological response. The patient remains disease-free posttreatment, with no evidence of recurrence on follow-up imaging. This case challenges the conventional paradigm that EGFR -mutated NSCLC does not benefit from immunotherapy, highlighting the potential for an alternative treatment approach in rare subtypes such as PSC. Our findings emphasize the importance of comprehensive molecular profiling and a personalized treatment strategy to optimize outcomes in aggressive and refractory lung cancers.

Schlagwörter

Stichwörter der Autor:innen

EGFR mutationimmunotherapypulmonary sarcomatoid carcinoma (PSC)

Autor:innen und Institutionen

  • Imperial College London, London, United Kingdom.
  • Department of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
  • Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.
  • Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India.
  • Datar Cancer Genetics, Nashik, Maharashtra, India.
  • Department of Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.

ORCID-Profile: Sewanti Limaye

Zitieren

APA

Gianchandani, A., Desai, D., Sambath, J., Patil, D., Kumar, P., Singh, S., Madre, C., Deshpande, R., Parab, A., Shah, N., Shah, D., Kataria, P., Atluri, S., Mehta, M., Shreenivas, A., Datar, R., Kurzrock, R., & Limaye, S. (2025). Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report. Journal of Immunotherapy and Precision Oncology, 8(3), 206-211. https://doi.org/10.36401/jipo-25-7

Vancouver

Gianchandani A, Desai D, Sambath J, Patil D, Kumar P, Singh S, et al. Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report. Journal of Immunotherapy and Precision Oncology. 2025;8(3):206-211. doi:10.36401/jipo-25-7

BibTeX
@article{Gianchandani2025,
  author = {Gianchandani, Ayushi and Desai, Darshana and Sambath, Janani and Patil, Darshana and Kumar, Prashant and Singh, Shambhavi and Madre, Chetan and Deshpande, Ruturaj and Parab, Anjali and Shah, Niyati and Shah, Darshit and Kataria, Pritam and Atluri, Shrikanth and Mehta, Marzi and Shreenivas, Aditya and Datar, Rajan and Kurzrock, Razelle and Limaye, Sewanti},
  title = {Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2025},
  volume = {8},
  number = {3},
  pages = {206--211},
  doi = {10.36401/jipo-25-7}
}
Kostenlos starten →